How does LUNB's PE Ratio compare to its peers?

LUNB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (23.2x).

How does LUNB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

LUNB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the European Pharmaceuticals industry average (20.7x).

What is LUNB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate LUNB's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of LUNB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

LUNB (€6) is trading below our estimate of [[fair value]] (€21.86)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

H. Lundbeck (WBAG:LUNB) - Stock Price, News & Analysis

LUNB Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

LUNB fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	3/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 72.6% below our estimate of its fair value

Earnings are forecast to grow 8.57% per year

Earnings have grown 7% per year over the past 5 years

Risk Analysis

No risks detected for LUNB from our risk checks.

H. Lundbeck A/S Competitors

Changchun High-Tech Industry (Group)

SZSE:000661

CN¥44.4b

Orion Oyj

HLSE:ORNBV

€6.3b

Sichuan Kelun Pharmaceutical

SZSE:002422

CN¥49.4b

Abbott India

BSE:500488

₹581.1b

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	DKK 6.00
52 Week High	DKK 6.62
52 Week Low	DKK 4.26
Beta	0.18
11 Month Change	-5.89%
3 Month Change	2.74%
1 Year Change	33.82%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	24.27%

Recent updates

Shareholder Returns

	LUNB	AT Pharmaceuticals	AT Market
7D	2.4%	-3.3%	0.9%
1Y	33.8%	3.5%	1.5%

Return vs Industry: LUNB exceeded the Austrian Pharmaceuticals industry which returned 3.5% over the past year.

Return vs Market: LUNB exceeded the Austrian Market which returned 1.5% over the past year.

Price Volatility

Is LUNB's price volatile compared to industry and market?
LUNB volatility
LUNB Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	3.6%
10% most volatile stocks in AT Market	6.3%
10% least volatile stocks in AT Market	1.8%

Stable Share Price: LUNB has not had significant price volatility in the past 3 months compared to the Austrian market.

Volatility Over Time: LUNB's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1951	5,800	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
LUNB fundamental statistics
Market cap	€5.72b
Earnings (TTM)	€360.22m
Revenue (TTM)	€2.87b

16.5x

P/E Ratio

2.1x

P/S Ratio

Is LUNB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUNB income statement (TTM)
Revenue	DKK 21.44b
Cost of Revenue	DKK 4.37b
Gross Profit	DKK 17.07b
Other Expenses	DKK 14.39b
Earnings	DKK 2.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)	2.71
Gross Margin	79.63%
Net Profit Margin	12.53%
Debt/Equity Ratio	15.6%

How did LUNB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

26%

Payout Ratio

LUNB Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

SZSE:000661

CN¥44.4b

HLSE:ORNBV

€6.3b

SZSE:002422

CN¥49.4b

BSE:500488

₹581.1b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023)

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

Dividend of kr.0.70 announced

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Shareholder Returns

Price Volatility

About the Company

H. Lundbeck A/S Fundamentals Summary

16.5x

2.1x

Earnings & Revenue

Dividends

1.6%

26%